Tecvayli plus Darzalex led to an 83% boost to progression-free survival versus the current standard therapy in relapsed or ...

While traditional induction therapy for newly diagnosed stage 2 myeloma often focuses on combinations of proteasome inhibitors, immunomodulatory drugs, and steroids, these newer immunotherapy classes ...

Hearn Jay Cho, MD, PhD, chief medical officer at the Multiple Myeloma Research Foundation, shared insights on what end points ...

A clinical team from the Department of Medicine, School of Clinical Medicine at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed), in collaboration with Queen Mary Hospital, has ...

Multiple myeloma is a rare type of blood cancer that starts in your plasma cells. Your plasma cells are a type of white blood cell inside your bone marrow, the soft inner part of your bones. If you ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Treating late stage myeloma has multiple ...

Rural America regularly presents some of the greatest challenges to quality myeloma care and cancer care in general. Though perhaps extreme, one example quickly came to mind for Daniel Nikcevich, MD, ...

FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention.

The blood cancer multiple myeloma, which involves infection-fighting plasma cells in the bone marrow, affects only about 1% of all cancers -- predominantly individuals over age 65. The disease ...

Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...

After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder. J ...